170 related articles for article (PubMed ID: 37792729)
1. Safety and clinical efficacy of an anti-PD-L1 antibody (c4G12) in dogs with advanced malignant tumours.
Maekawa N; Konnai S; Hosoya K; Kim S; Kinoshita R; Deguchi T; Owaki R; Tachibana Y; Yokokawa M; Takeuchi H; Kagawa Y; Takagi S; Ohta H; Kato Y; Yamamoto S; Yamamoto K; Suzuki Y; Okagawa T; Murata S; Ohashi K
PLoS One; 2023; 18(10):e0291727. PubMed ID: 37792729
[TBL] [Abstract][Full Text] [Related]
2. A canine chimeric monoclonal antibody targeting PD-L1 and its clinical efficacy in canine oral malignant melanoma or undifferentiated sarcoma.
Maekawa N; Konnai S; Takagi S; Kagawa Y; Okagawa T; Nishimori A; Ikebuchi R; Izumi Y; Deguchi T; Nakajima C; Kato Y; Yamamoto K; Uemura H; Suzuki Y; Murata S; Ohashi K
Sci Rep; 2017 Aug; 7(1):8951. PubMed ID: 28827658
[TBL] [Abstract][Full Text] [Related]
3. PD-L1 immunohistochemistry for canine cancers and clinical benefit of anti-PD-L1 antibody in dogs with pulmonary metastatic oral malignant melanoma.
Maekawa N; Konnai S; Nishimura M; Kagawa Y; Takagi S; Hosoya K; Ohta H; Kim S; Okagawa T; Izumi Y; Deguchi T; Kato Y; Yamamoto S; Yamamoto K; Toda M; Nakajima C; Suzuki Y; Murata S; Ohashi K
NPJ Precis Oncol; 2021 Feb; 5(1):10. PubMed ID: 33580183
[TBL] [Abstract][Full Text] [Related]
4. Enhanced Systemic Antitumour Immunity by Hypofractionated Radiotherapy and Anti-PD-L1 Therapy in Dogs with Pulmonary Metastatic Oral Malignant Melanoma.
Deguchi T; Maekawa N; Konnai S; Owaki R; Hosoya K; Morishita K; Nakamura M; Okagawa T; Takeuchi H; Kim S; Kinoshita R; Tachibana Y; Yokokawa M; Takagi S; Kato Y; Suzuki Y; Murata S; Ohashi K
Cancers (Basel); 2023 Jun; 15(11):. PubMed ID: 37296981
[TBL] [Abstract][Full Text] [Related]
5. Exploration of serum biomarkers in dogs with malignant melanoma receiving anti-PD-L1 therapy and potential of COX-2 inhibition for combination therapy.
Maekawa N; Konnai S; Asano Y; Sajiki Y; Deguchi T; Okagawa T; Watari K; Takeuchi H; Takagi S; Hosoya K; Kim S; Ohta H; Kato Y; Suzuki Y; Murata S; Ohashi K
Sci Rep; 2022 Jun; 12(1):9265. PubMed ID: 35665759
[TBL] [Abstract][Full Text] [Related]
6. Proof-of-concept study of the caninized anti-canine programmed death 1 antibody in dogs with advanced non-oral malignant melanoma solid tumors.
Igase M; Inanaga S; Nishibori S; Itamoto K; Sunahara H; Nemoto Y; Tani K; Horikirizono H; Nakaichi M; Baba K; Kambayashi S; Okuda M; Sakai Y; Sakurai M; Kato M; Tsukui T; Mizuno T
J Vet Sci; 2024 Jan; 25(1):e15. PubMed ID: 38311328
[TBL] [Abstract][Full Text] [Related]
7. Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial.
Geoerger B; Kang HJ; Yalon-Oren M; Marshall LV; Vezina C; Pappo A; Laetsch TW; Petrilli AS; Ebinger M; Toporski J; Glade-Bender J; Nicholls W; Fox E; DuBois SG; Macy ME; Cohn SL; Pathiraja K; Diede SJ; Ebbinghaus S; Pinto N
Lancet Oncol; 2020 Jan; 21(1):121-133. PubMed ID: 31812554
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical Analysis of PD-L1 Expression in Canine Malignant Cancers and PD-1 Expression on Lymphocytes in Canine Oral Melanoma.
Maekawa N; Konnai S; Okagawa T; Nishimori A; Ikebuchi R; Izumi Y; Takagi S; Kagawa Y; Nakajima C; Suzuki Y; Kato Y; Murata S; Ohashi K
PLoS One; 2016; 11(6):e0157176. PubMed ID: 27276060
[TBL] [Abstract][Full Text] [Related]
9. Oral malignant melanomas and other head and neck neoplasms in Danish dogs--data from the Danish Veterinary Cancer Registry.
Brønden LB; Eriksen T; Kristensen AT
Acta Vet Scand; 2009 Dec; 51(1):54. PubMed ID: 20021647
[TBL] [Abstract][Full Text] [Related]
10. A pilot clinical study of the therapeutic antibody against canine PD-1 for advanced spontaneous cancers in dogs.
Igase M; Nemoto Y; Itamoto K; Tani K; Nakaichi M; Sakurai M; Sakai Y; Noguchi S; Kato M; Tsukui T; Mizuno T
Sci Rep; 2020 Oct; 10(1):18311. PubMed ID: 33110170
[TBL] [Abstract][Full Text] [Related]
11. Long-term survival of dogs with stage 4 oral malignant melanoma treated with anti-canine PD-1 therapeutic antibody: A follow-up case report.
Igase M; Inanaga S; Tani K; Nakaichi M; Sakai Y; Sakurai M; Kato M; Tsukui T; Mizuno T
Vet Comp Oncol; 2022 Dec; 20(4):901-905. PubMed ID: 35535636
[TBL] [Abstract][Full Text] [Related]
12. Multi-institutional retrospective study of canine foot pad malignant melanomas: 20 cases.
Jeon MD; Leeper HJ; Cook MR; McMillan SK; Bennett T; Murray CA; Tripp CD; Curran KM
Vet Comp Oncol; 2022 Dec; 20(4):854-861. PubMed ID: 35771690
[TBL] [Abstract][Full Text] [Related]
13. Spontaneous tumors in dogs and cats: models for the study of cancer biology and treatment.
MacEwen EG
Cancer Metastasis Rev; 1990 Sep; 9(2):125-36. PubMed ID: 2253312
[TBL] [Abstract][Full Text] [Related]
14. A retrospective analysis of the efficacy of Oncept vaccine for the adjunct treatment of canine oral malignant melanoma.
Ottnod JM; Smedley RC; Walshaw R; Hauptman JG; Kiupel M; Obradovich JE
Vet Comp Oncol; 2013 Sep; 11(3):219-29. PubMed ID: 23909996
[TBL] [Abstract][Full Text] [Related]
15. Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial.
Herbst RS; Arkenau HT; Santana-Davila R; Calvo E; Paz-Ares L; Cassier PA; Bendell J; Penel N; Krebs MG; Martin-Liberal J; Isambert N; Soriano A; Wermke M; Cultrera J; Gao L; Widau RC; Mi G; Jin J; Ferry D; Fuchs CS; Petrylak DP; Chau I
Lancet Oncol; 2019 Aug; 20(8):1109-1123. PubMed ID: 31301962
[TBL] [Abstract][Full Text] [Related]
16. Inhibitory Effects of a Reengineered Anthrax Toxin on Canine Oral Mucosal Melanomas.
Nishiya AT; Nagamine MK; Fonseca IIMD; Miraldo AC; Scattone NV; Guerra JL; Xavier JG; Santos M; Gomes COMS; Ward JM; Liu S; Leppla SH; Bugge TH; Dagli MLZ
Toxins (Basel); 2020 Mar; 12(3):. PubMed ID: 32121654
[TBL] [Abstract][Full Text] [Related]
17. Comparison of BNCT and GdNCT efficacy in treatment of canine cancer.
Mitin VN; Kulakov VN; Khokhlov VF; Sheino IN; Arnopolskaya AM; Kozlovskaya NG; Zaitsev KN; Portnov AA
Appl Radiat Isot; 2009 Jul; 67(7-8 Suppl):S299-301. PubMed ID: 19428264
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of cisplatin combined with piroxicam for the treatment of oral malignant melanoma and oral squamous cell carcinoma in dogs.
Boria PA; Murry DJ; Bennett PF; Glickman NW; Snyder PW; Merkel BL; Schlittler DL; Mutsaers AJ; Thomas RM; Knapp DW
J Am Vet Med Assoc; 2004 Feb; 224(3):388-94. PubMed ID: 14765798
[TBL] [Abstract][Full Text] [Related]
19. Association of tumour-infiltrating regulatory T cells with adverse outcomes in dogs with malignant tumours.
Sakai K; Maeda S; Yamada Y; Chambers JK; Uchida K; Nakayama H; Yonezawa T; Matsuki N
Vet Comp Oncol; 2018 Sep; 16(3):330-336. PubMed ID: 29322606
[TBL] [Abstract][Full Text] [Related]
20. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.
Garassino MC; Cho BC; Kim JH; Mazières J; Vansteenkiste J; Lena H; Corral Jaime J; Gray JE; Powderly J; Chouaid C; Bidoli P; Wheatley-Price P; Park K; Soo RA; Huang Y; Wadsworth C; Dennis PA; Rizvi NA;
Lancet Oncol; 2018 Apr; 19(4):521-536. PubMed ID: 29545095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]